 |
HemoGenix, Inc |
ALLIANCE PARTNERS
HemoGenix, Inc.
HemoGenix® owns patented and patent-pending technology for analysis of stem cells known as the HALO® assay platform which is based on advanced measurement of ATP cellular content. HALO® assays are now industry standard methods for quality and potency determination of hematopoietic stem cells and also allow sophisticated analysis of toxic effects of drugs and new drug candidates including cancer chemotherapeutic agents. Vitro and HemoGenix have recently formed an alliance to develop, manufacture and distribute new HALO® assays for additional stem cells including MSC and iPS cells. See press release dated April 28, 2010
Downloadable flyer:
Luminescence Detection of Human Mesenchymal Stem Cells (HuMSC)
Alliance Partners
HemoGenix® | NacalaiTesque, Inc.